Innovent Biologics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Innovent Biologics, Inc.
US Secretary of Commerce Gina Raimondo has made the first official visit to China by a US commerce official in three years, paving the way to possible improvements in bilateral relations. Despite ongoing geopolitical tensions as a major concern for US firms in China, some are returning to growth in the country.
If the bill on the Biosimilar Red Tape Elimination Act is passed, all biosimilars would be deemed interchangeable on US FDA approval. Scrip takes a look at what empowering pharmacists could mean, what the generics substitution experience shows and where possible pain points lie
Sintbilo (tafolecimab) is the first among four late-stage domestically developed PCSK9 Inhibitors to win the nod from China’s drug regulator. Despite lack of public reimbursement coverage, the drug could potentially unseat same-class rivals from Amgen and Sanofi/Regeneron.
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Innovent Biologics (Suzhou) Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.